Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes

(MedPage Today) -- Low-dose hypomethylating agents (HMAs) was associated with favorable outcomes in previously untreated lower-risk myelodysplastic syndromes (MDS), according to a long-term analysis of a randomized phase II study.
With a follow...